These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. IL-5-producing CD4 Blomberg OS; Spagnuolo L; Garner H; Voorwerk L; Isaeva OI; van Dyk E; Bakker N; Chalabi M; Klaver C; Duijst M; Kersten K; Brüggemann M; Pastoors D; Hau CS; Vrijland K; Raeven EAM; Kaldenbach D; Kos K; Afonina IS; Kaptein P; Hoes L; Theelen WSME; Baas P; Voest EE; Beyaert R; Thommen DS; Wessels LFA; de Visser KE; Kok M Cancer Cell; 2023 Jan; 41(1):106-123.e10. PubMed ID: 36525971 [TBL] [Abstract][Full Text] [Related]
5. Exercise Training Improves Tumor Control by Increasing CD8 Gomes-Santos IL; Amoozgar Z; Kumar AS; Ho WW; Roh K; Talele NP; Curtis H; Kawaguchi K; Jain RK; Fukumura D Cancer Immunol Res; 2021 Jul; 9(7):765-778. PubMed ID: 33839688 [TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Oba T; Kajihara R; Yokoi T; Repasky EA; Ito F Cancer Res; 2021 Dec; 81(24):6183-6195. PubMed ID: 34666993 [TBL] [Abstract][Full Text] [Related]
7. Regulatory T lymphocyte infiltration in metastatic breast cancer-an independent prognostic factor that changes with tumor progression. Stenström J; Hedenfalk I; Hagerling C Breast Cancer Res; 2021 Feb; 23(1):27. PubMed ID: 33602289 [TBL] [Abstract][Full Text] [Related]
8. Evaluating the immunologically "cold" tumor microenvironment after treatment with immune checkpoint inhibitors utilizing PET imaging of CD4 + and CD8 + T cells in breast cancer mouse models. Lu Y; Houson HA; Gallegos CA; Mascioni A; Jia F; Aivazian A; Song PN; Lynch SE; Napier TS; Mansur A; Larimer BM; Lapi SE; Hanker AB; Sorace AG Breast Cancer Res; 2024 Jun; 26(1):104. PubMed ID: 38918836 [TBL] [Abstract][Full Text] [Related]
9. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3. Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262 [TBL] [Abstract][Full Text] [Related]
10. Rapid Depletion of Intratumoral Regulatory T Cells Induces Synchronized CD8 T- and NK-cell Activation and IFNγ-Dependent Tumor Vessel Regression. Kurebayashi Y; Olkowski CP; Lane KC; Vasalatiy OV; Xu BC; Okada R; Furusawa A; Choyke PL; Kobayashi H; Sato N Cancer Res; 2021 Jun; 81(11):3092-3104. PubMed ID: 33574087 [TBL] [Abstract][Full Text] [Related]
11. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349 [TBL] [Abstract][Full Text] [Related]
12. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. Isaacs J; Anders C; McArthur H; Force J Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085 [TBL] [Abstract][Full Text] [Related]
13. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation. Milling LE; Garafola D; Agarwal Y; Wu S; Thomas A; Donahue N; Adams J; Thai N; Suh H; Irvine DJ Cancer Immunol Res; 2022 Jan; 10(1):26-39. PubMed ID: 34686488 [TBL] [Abstract][Full Text] [Related]
15. Activin A Promotes Regulatory T-cell-Mediated Immunosuppression in Irradiated Breast Cancer. De Martino M; Daviaud C; Diamond JM; Kraynak J; Alard A; Formenti SC; Miller LD; Demaria S; Vanpouille-Box C Cancer Immunol Res; 2021 Jan; 9(1):89-102. PubMed ID: 33093219 [TBL] [Abstract][Full Text] [Related]
16. Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients. Bailur JK; Gueckel B; Derhovanessian E; Pawelec G Breast Cancer Res; 2015 Mar; 17(1):34. PubMed ID: 25849846 [TBL] [Abstract][Full Text] [Related]
17. A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. Chen IX; Newcomer K; Pauken KE; Juneja VR; Naxerova K; Wu MW; Pinter M; Sen DR; Singer M; Sharpe AH; Jain RK Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23684-23694. PubMed ID: 32907939 [TBL] [Abstract][Full Text] [Related]
18. NR0B2 re-educates myeloid immune cells to reduce regulatory T cell expansion and progression of breast and other solid tumors. Vidana Gamage HE; Shahoei SH; Wang Y; Jacquin E; Weisser E; Bautista RO; Henn MA; Schane CP; Nelczyk AT; Ma L; Das Gupta A; Bendre SV; Nguyen T; Tiwari S; Tjoanda E; Krawczynska N; He S; Albright ST; Farmer R; Smith AJ; Fink EC; Chen H; Sverdlov M; Gann PH; Boidot R; Vegran F; Fanning SW; Hergenrother PJ; Apetoh L; Nelson ER Cancer Lett; 2024 Aug; 597():217042. PubMed ID: 38908543 [TBL] [Abstract][Full Text] [Related]
19. High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade. Chua KLM; Fehlings M; Yeo ELL; Nardin A; Sumatoh H; Chu PL; Nei WL; Ong EHW; Woo WY; Low KP; Wang H; Poon DJJ; Liang ZG; Yao K; Huang L; Toh CK; Ang MK; Farid M; Cheng XM; Kanesvaran R; Dent R; Wee JTS; Lim TKH; Iyer NG; Tan DSW; Soo KC; Newell EW; Chua MLK Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):70-80. PubMed ID: 32544576 [TBL] [Abstract][Full Text] [Related]
20. Development of NR0B2 as a therapeutic target for the re-education of tumor associated myeloid cells. Vidana Gamage HE; Albright ST; Smith AJ; Farmer R; Shahoei SH; Wang Y; Fink EC; Jacquin E; Weisser E; Bautista RO; Henn MA; Schane CP; Nelczyk AT; Ma L; Das Gupta A; Bendre SV; Nguyen T; Tiwari S; Krawczynska N; He S; Tjoanda E; Chen H; Sverdlov M; Gann PH; Boidot R; Vegran F; Fanning SW; Apetoh L; Hergenrother PJ; Nelson ER Cancer Lett; 2024 Aug; 597():217086. PubMed ID: 38944231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]